It seems that the do-all, fix-all, be-all for kidney problems is either an ARB or ACE-I. We start patients on these medications at the first sign of elevated glucose levels regardless of their blood pressure levels, as they “protect” the kidneys. This is definitely true, but what do we do …

This patient was newly diagnosed, but I did not really think she believed she had diabetes. In other words, she was in denial. Once she saw the results of her labs, I could see things changed in her. She “got it."

In part 1 of this Exclusive Interview, Michael Hill discusses the release of the hybrid closed-loop system, the Minimed 670G.

In this week's Homerun Slides, therapeutic approaches for chronic kidney disease beyond Renin-angiotensin system (RAS) blockade.

Gluconeogenic pathways: Gluconeogenesis is the synthesis of glucose from three carbon precursors such as alanine, pyruvate, lactate, and glycerol and is essentially a reversal of glycolysis. Under normal conditions, 90% of gluconeogenesis occurs in liver, and the rest occurs mainly in the renal cortex. Other sites of gluconeogenesis, such as the small intestine have been suggested but remain controversial.

Most of the time when we speak about patients who are not diagnosed with diabetes and who develop complications, we are usually referring to vision changes or things like neuropathy. However, it now appears that there are a good number of these undiagnosed who die from ketoacidosis. This week, our …

New evidence questions the idea of what is normal.

A new finding from the SCALE trial.

Gastric bypass surgery may treat type 2 diabetes in selected patients.

Changes in serum metabolomic profile affect eGFR in patients with type 1 diabetes.